Health Sciences Authority (HSA) is Singapore’s national authority regulating health products, including medications. Every month, HSA publishes a list of medications that are newly approved or medications with newly approved indication(s). This list can be found on HSA’s website.
July 2021
- New drugs approved: 6
- New drug indications approved: 1
New drugs approved
| Product name | Active ingredient(s) | Dosage Form | Strength of dosage form | Route of Administration | Indication(s) | Pharmaceutical company | Approval Date |
| Hyrimoz | Adalimumab | Pre-Filled Syringe/Pen | 40mg/0.8mL | Injection | (i) Rheumatoid Arthritis (adults) (ii) Psoriatic Arthritis (adults) (iii) Ankylosing Spondylitis (adults) (iv) Crohn’s Disease (adults and paediatrics) (v) Ulcerative Colitis (adults) (vi) Plaque Psoriasis (adults and paediatrics) (vii) Hidradenitis Suppurativa (adults and adolescent) (viii) Uveitis (adults and paediatrics) (ix) Idiopathic Arthritis (paedictrics) (x) Enthesitis-Related Arthritis (paediatrics) |
Novartis | 08 Jul 2021 |
| Zirabev | Bevacizumab | Vial | 100mg/4mL, 400mg/16mL |
Injection | (i) Metastatic Carcinoma of the Colon or Rectum (mCRC) (ii) Metastatic Breast Cancer (mBC) (iii) Non-Small Cell Lung Cancer (NSCLC) (iv) Malignant Glioma (WHO Grade IV) – Glioblastoma (v) Advanced and/or Metastatic Renal Cell Cancer (mRCC) (vi) Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer (vii) Cervical Cancer |
Pfizer | 26 Jul 2021 |
| Pertagen | Filamentous Haemagglutinin, Recombinant Pertussis Toxin | Vial | Not applicable | Injection | Active booster immunization against pertussis. Considered as an alternative to combined tetanus, diphtheria and acellular pertussis vaccines. | Novem Healthcare | 23 Jul 2021 |
| Accofil | Filgrastim | Pre-Filled Syringe/Pen | 30MU/0.5mL, 48MU/0.5mL |
Injection | (i) Established cytotoxic chemotherapy (ii) Peripheral blood progenitor cell mobilisation (PBPC) (iii) Severe chronic neutropenia (SCN) (iv) HIV infection |
Accord Healthcare | 08 Jul 2021 |
| Koselugo | Selumetinib | Capsule | 10mg, 25mg | Oral | Treatment of paediatric patients (3yo and above) with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) | AstraZeneca | 09 Jul 2021 |
| Technescan PYP | Sodium pyrophosphate decahydrate | Vial | 20mg | Injection | Diagnostic use | QT Instruments | 09 Jul 2021 |
New drug indications approved
| Product name | Active ingredient(s) | Dosage Form | Strength of dosage form | Route of Administration | Indication(s) | Pharmaceutical company | Approval Date |
| Bavencio | Avelumab | Vial | 200mg/10mL | Injection | First-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) | Merck | 01 Jul 2021 |
